ロード中...
P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA
Bevacizumab is registered in the U.S. for the treatment of recurrent glioblastoma based on improved PFS in uncontrolled phase II trials; Recently, a randomized controlled phase II trial studied lomustin, bevacizumab or the combination of both compounds in the treatment of glioblastoma at first recur...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4185719/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.352 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|